Manhattan Medical Weight Loss, P.C.

Home
United States
New York, NY
Manhattan Medical Weight Loss, P.C.

Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Manhattan Medical Weight Loss, P.C., Medical and health, 369 Lexington Avenue, New York, NY.

05/19/2025

Your healthiest weight isn’t just about the scale—it’s about better blood pressure 💓, balanced insulin 💉, lower cholesterol 🧬, and moving through life with more energy and ease 🚶‍♀️💪.

It’s about sleeping better 😴, feeling stronger, and living longer 🧠✨.

Let’s focus on your health, not just your weight. 💚

👉 Schedule a free consultation at www.mmweightloss.com

Medicine

03/05/2025

🚨 Big news in weight loss meds! 🚨

Novo Nordisk just launched their own direct-to-consumer pharmacy, offering Wegovy for $500/month—a drop from the usual $650 with a coupon at regular pharmacies, or ~$1350 without coupon💰📉

This move follows Eli Lilly’s push to make more Zepbound vial doses available at lower prices through their DTC pharmacy.

👏 A step in the right direction, but we need better insurance coverage & even lower costs to truly improve access!

02/25/2025

Eli Lilly just announced more doses of Zepbound will be available in the cheaper vial option, AND the cost of existing doses is going down! 🎉💰

💉 What’s new?
✅ 7.5mg & 10mg doses now available!
✅ Price reductions for 2.5mg & 5.0mg

💰 New Cost Breakdown:
🔹 2.5mg: $399 ➡️ $349
🔹 5.0mg: $550 ➡️ $449
🔹 7.5mg: $449 (first fill & refills within 45 days, otherwise $599)
🔹 10.0mg: $449 (first fill & refills within 45 days, otherwise $699)

📢 This is a step in the right direction for patients without coverage, though affordability is still a challenge and the cost still needs to go down further for more access. 💙

📞 Schedule a free phone consultation today! 👉 www.mmweightloss.com

02/18/2025

📢 Semaglutide & Alcohol Reduction Study Results 📢
🔥 Many people report reduced alcohol cravings on incretin medications like semaglutide (Wegovy/Ozempic) & tirzepatide (Zepbound/Mounjaro)—now studies are confirming it!

🧪 New Phase 2 Study in JAMA Psychiatry looked at semaglutide in alcohol use disorder (AUD).
doi:10.1001/jamapsychiatry.2024.4789

📝 Study Design:
🔹 Double-blind, randomized trial over 9 weeks
🔹 48 participants (71% women)
🔹 Low-dose semaglutide: 4 weeks at 0.25mg, 4 weeks at 0.5mg, 1 week at 1.0mg

✅ Key Findings:
🔹 Lower alcohol intake: Medium to large effect in reducing grams of alcohol & peak breath alcohol concentration.
🔹 Fewer heavy drinking days: Significant decline over time in the semaglutide group.
🔹 Reduced cravings: Weekly craving scores dropped significantly.
🔹 Bonus effect: Cigarette use declined more in the semaglutide group.
🔹 Weight loss: Participants lost ~5% body weight, while placebo showed no change.

💊 Safety: No serious adverse effects or alcohol-related interactions.

Overall, given this was a phase 2 trial it included a small number of participants over a short period of time, but it is promising that low doses of GLP medications can offer an alternative treatment option!

01/10/2025

🌟 Breaking News! 🌟
📣 Medicare is set to start covering Zepbound (tirzepatide) for the treatment of moderate to severe sleep apnea! 🛌💤

Key Points to Know:
✅ Coverage criteria must be met, and these may vary by state and Medicare Part D plan. Examples may include:

BMI thresholds 📊
Sleep apnea severity 💤
Timing of the last sleep study 🕒
Trial/failure of CPAP use 🛏️

❌ This does NOT apply to commercial insurance plans yet, but commercial plans often follow Medicare’s lead. 🤞 Widespread coverage could be coming soon!

Background on Zepbound:
💉 Zepbound (tirzepatide) is a once-weekly injectable GLP/GIP receptor agonist.
🔬 The SURMOUNT-OSA trial showed it significantly reduced the severity of obstructive sleep apnea, even without CPAP.

This is a major step forward for innovative sleep apnea treatments! 💪✨

11/26/2024

There are currently archaic laws in place that prevent Medicare from covering weight loss medications. When Medicare covers a class of medications, then private insurances typically follow its lead.

If this passes it will have huge health benefits and go a far way in bridging health disparities and give access to these life prolonging treatments. It will hopefully also pave the way for negotiating to decrease the cost of GLP medications like Wegovy (semaglutide) and Zepbound (tirzepatide).

Of course we also need to advocate to improve our food environment, but even with those changes it will take a lot time to see the health impacts so it’s important to make sure people have access to safe and effective treatments now.

11/15/2024

🚨 Breakthrough results for ! 🚨

The 3-year SURMOUNT-1 study shows sustained average weight loss of 22.9% and a 94% reduced risk of developing type 2 diabetes in adults with pre-diabetes and obesity.

💉Tirzepatide is a GLP/GIP Receptor agonist used in the treatment of overweight and obesity (as Zepbound) and in the treatment of diabetes (as Mounjaro).

🌟 Published in NEJM, these findings highlight tirzepatide’s potential to transform long-term weight and diabetes management.

💪 Having more long term safety and efficacy data is an important part of management of these chronic metabolic conditions.

07/31/2024

🌟 My Movement Recommendations for Optimal Metabolic Health 🌟

As an obesity medicine doctor, here are my top tips for achieving optimal metabolic health. Remember, you don’t need to do this from day one and can work up to it!

1️⃣ Walk 5,000-10,000 steps per day 🚶‍♀️🚶‍♂️
This ensures you’re not sedentary and moving regularly throughout the day.

2️⃣ Strength training 2x per week 💪🏋️‍♂️🏋️‍♀️
Resistance and strength training are crucial for bone health, building muscle mass, and improving balance.

3️⃣ Cardio exercises 2x per week ❤️🏃‍♀️🏃‍♂️
Cardio exercises that increase your heart rate are essential for cardiovascular health.

Choose activities you enjoy and can sustain. Consistency is key!

06/25/2024

📣The first generic GLP-1 medication will soon be available 🎉

Liraglutide, brand name Victoza for the treatment of Diabetes and Saxenda for the treatment of weight loss, will soon be available as a generic medication by Teva.

- Max dose will be 1.8mg which is for diabetes management, not weight loss. (Up to 3.0mg for weight loss)
- No announcements have been made yet about the cost or if the higher doses used for weight loss will be available in the future.

This is an exciting development in having more accessible and hopefully affordable treatments.

05/28/2024

Breaking News! 🚨

The FLOW trial, just published in the NEJM, reveals the protective effects of semaglutide for people with Type 2 diabetes and Chronic Kidney Disease. The study reports a 20% reduction in all-cause mortality among participants.

Background:
-Approximately 11.6% of the US population has diabetes.
-Diabetes is the leading cause of kidney failure in the US, responsible for nearly half of new cases.
-People with diabetes and kidney disease are at high risk of cardiovascular disease.
It was previously unknown if semaglutide could mitigate this risk.

Study Design:
-3500 participants with Type 2 diabetes and chronic kidney disease from 28 countries.
-Randomly assigned to semaglutide 1mg or placebo.
-Monitored over an average of 3.4 years.

Findings:
-Slowed progression of chronic kidney disease.
-Decreased death from cardiovascular disease.
-Decreased death from all causes.

Takeaways:
-GLP-1 treatment is about more than cosmetic weight loss—there are significant health benefits!
-While semaglutide isn’t FDA-approved for chronic kidney disease yet, it is approved for treating Type 2 diabetes and reducing cardiovascular risk.

04/12/2024

🌟 Transform your health! 🌟
The ultimate aim of weight loss? Boosting metabolic health and fortifying strength by losing fat cells while preserving muscle! 💪✨

It’s all about nourishing your body right during this journey to achieve these goals. Whether you’re embracing lifestyle changes alone or incorporating medications, these principles remain steadfast.

Book your complimentary phone consultation with Dr. Koohsari at www.mmweightloss.com! 📞💼

Address

369 Lexington Avenue
New York, NY
10016

Telephone

+12126519197

Website

http://www.mmweightloss.com/

Alerts

Be the first to know and let us send you an email when Manhattan Medical Weight Loss, P.C. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Manhattan Medical Weight Loss, P.C.: